Immunotherapy

Results: 985



#Item
11JOB DESCRIPTION – Associate Director/Director, Clinical Development Operations A. Organization The Parker Institute for Cancer Immunotherapy is an unprecedented collaboration between the country’s leading immunologis

JOB DESCRIPTION – Associate Director/Director, Clinical Development Operations A. Organization The Parker Institute for Cancer Immunotherapy is an unprecedented collaboration between the country’s leading immunologis

Add to Reading List

Source URL: www.parkerici.org

- Date: 2016-12-09 15:56:02
    12Immunotherapy Combinations TRANSCRIPT & FIGURES ©2015 GRACE - All Rights Reserved  cancerGRACE.org

    Immunotherapy Combinations TRANSCRIPT & FIGURES ©2015 GRACE - All Rights Reserved cancerGRACE.org

    Add to Reading List

    Source URL: cancergrace.org

    - Date: 2016-04-26 18:44:02
      1312th International Workshop IMMUNOTHERAPY 2016 Hotel Nacional de Cuba / October 17‐21, Havana, Cuba REGISTRATION FORM Please complete one registration form per participant, including accompanying persons not att

      12th International Workshop IMMUNOTHERAPY 2016 Hotel Nacional de Cuba / October 17‐21, Havana, Cuba REGISTRATION FORM Please complete one registration form per participant, including accompanying persons not att

      Add to Reading List

      Source URL: www.immunotherapy.cim.co.cu

      - Date: 2016-08-03 09:55:42
        14Building a world-class specialty biopharmaceutical business Interim report and accounts 2015 Contents 01	 Introduction from the Chief Executive

        Building a world-class specialty biopharmaceutical business Interim report and accounts 2015 Contents 01 Introduction from the Chief Executive

        Add to Reading List

        Source URL: www.circassia.com

        Language: English - Date: 2015-11-05 09:21:40
        1520160404_Anergis_Closes_CHF_5_Million_Financing_Round_Extension_to_Conduct_the_ATIBAR_Trial

        20160404_Anergis_Closes_CHF_5_Million_Financing_Round_Extension_to_Conduct_the_ATIBAR_Trial

        Add to Reading List

        Source URL: www.biomedvc.com

        Language: English - Date: 2016-04-04 05:01:38
        16VAXIMM initiates Phase 1 translational study in glioblastoma with oral T-cell immunotherapy, VXM01 Basel (Switzerland) and Mannheim (Germany), July 12, 2016 – VAXIMM AG, a Swiss/German biotech company focused on develo

        VAXIMM initiates Phase 1 translational study in glioblastoma with oral T-cell immunotherapy, VXM01 Basel (Switzerland) and Mannheim (Germany), July 12, 2016 – VAXIMM AG, a Swiss/German biotech company focused on develo

        Add to Reading List

        Source URL: sunstone.eu

        Language: English - Date: 2016-07-12 04:22:18
        17Cover Conference-at-a-Glance Final Agenda Eighth Annual

        Cover Conference-at-a-Glance Final Agenda Eighth Annual

        Add to Reading List

        Source URL: www.giievent.jp

        Language: English - Date: 2016-08-16 03:53:14
        18F-star announces funding and collaboration extension with new Christian Doppler Lab for Innovative Immunotherapeutics Strong academic bridge supports F-star’s leading, innovative position in immuno-oncology and bispeci

        F-star announces funding and collaboration extension with new Christian Doppler Lab for Innovative Immunotherapeutics Strong academic bridge supports F-star’s leading, innovative position in immuno-oncology and bispeci

        Add to Reading List

        Source URL: www.f-star.com

        Language: English - Date: 2016-07-13 10:00:22
        1917427_UKW_AG-Bumm_Postdoc.cdr

        17427_UKW_AG-Bumm_Postdoc.cdr

        Add to Reading List

        Source URL: www.labtimes.org

        Language: English - Date: 2016-08-05 06:11:11
        20PRESS RELEASE – IMMUNOCORE LIMITED  Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma (Oxford, UK, 30 MarchImmunocore, a world-leading biotechnology company developing novel T cell

        PRESS RELEASE – IMMUNOCORE LIMITED Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma (Oxford, UK, 30 MarchImmunocore, a world-leading biotechnology company developing novel T cell

        Add to Reading List

        Source URL: www.immunocore.com

        Language: English - Date: 2016-03-29 05:35:06